Derek Cowsert

News
Tumor-Infiltrating Lymphocytes Exhibit Prognostic Value in Low-Risk Ductal Carcinoma in Situ
08/25/2022
Study findings demonstrate the efficacy of tumor-infiltrating lymphocytes for predicting prognoses in patients with low-risk ductal carcinoma in situ.
Study findings demonstrate the efficacy of tumor-infiltrating lymphocytes for predicting prognoses in patients with low-risk ductal carcinoma in situ.
Study findings demonstrate the...
08/25/2022
Oncology
News
High Tumor Mutational Burden Associated With Improved Progression-Free Survival Among Patients With NSCLC
02/16/2023
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor...
02/16/2023
Oncology
News
Epigallocatechin-3-Gallate Plus Radiotherapy Reduces Radiation-Induced Dermatitis in Patients With Breast Cancer
06/14/2022
Epigallocatechin-3-gallate plus radiotherapy reduced radiation-induced dermatitis vs radiotherapy alone among patients with breast cancer in a phase 2 study.
Epigallocatechin-3-gallate plus radiotherapy reduced radiation-induced dermatitis vs radiotherapy alone among patients with breast cancer in a phase 2 study.
Epigallocatechin-3-gallate plus...
06/14/2022
Oncology
News
High Tumor Mutation Burden Associated With Improved Clinical Outcomes of Immune Checkpoint Inhibitors in NSCLC
10/25/2022
A multicenter cohort study identified TMB levels are associated with objective response rate, progression-free survival, and overall survival among patients who received PD-1/PD-L1 inhibition as treatment for advanced NSCLC.
A multicenter cohort study identified TMB levels are associated with objective response rate, progression-free survival, and overall survival among patients who received PD-1/PD-L1 inhibition as treatment for advanced NSCLC.
A multicenter cohort study...
10/25/2022
Oncology
News
HER2-E Biomarker Associated With Poor Aromatase Inhibitor Response and Worse Outcomes in ER-Positive/HER2-Positive Breast Cancer
11/11/2022
HER2-E and ERBB2 biomarkers play a role in resistance to aromatase inhibitors, as well as a higher risk of recurrence in patients with ER+/HER2+ breast cancer.
HER2-E and ERBB2 biomarkers play a role in resistance to aromatase inhibitors, as well as a higher risk of recurrence in patients with ER+/HER2+ breast cancer.
HER2-E and ERBB2 biomarkers play...
11/11/2022
Oncology
News
IHC Can Select Best Endometrial Cancer Candidates for Bevacizumab Plus Chemotherapy
07/28/2022
Determining p53 status by IHC can help select the patients with endometrial cancer most likely to experience survival benefit when treated with bevacizumab plus chemotherapy, according to a phase 2 study.
Determining p53 status by IHC can help select the patients with endometrial cancer most likely to experience survival benefit when treated with bevacizumab plus chemotherapy, according to a phase 2 study.
Determining p53 status by IHC...
07/28/2022
Oncology
News
FDA Approves Tremelimumab Plus Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC
11/11/2022
On November 10, 2022, the FDA granted approval to tremelimumab, in combination with durvalumab and platinum-based chemotherapy, for adult patients with metastatic NSCLC without an EFGR mutation or ALK aberrations.
On November 10, 2022, the FDA granted approval to tremelimumab, in combination with durvalumab and platinum-based chemotherapy, for adult patients with metastatic NSCLC without an EFGR mutation or ALK aberrations.
On November 10, 2022, the FDA...
11/11/2022
Oncology
News
Osimertinib for Patients With Progressive EGFR-Mutated T790M-Negative NSCLC
04/21/2023
Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.
Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.
Osimertinib demonstrated modest...
04/21/2023
Oncology
News
Pembrolizumab Plus Chemotherapy Improves OS vs Chemotherapy and Placebo in Advanced Triple-Negative Breast Cancer
08/25/2022
In a phase 3 study, pembrolizumab plus chemotherapy prolonged OS vs chemotherapy plus placebo among patients with advanced triple-negative breast cancer.
In a phase 3 study, pembrolizumab plus chemotherapy prolonged OS vs chemotherapy plus placebo among patients with advanced triple-negative breast cancer.
In a phase 3 study,...
08/25/2022
Oncology
Conference Coverage
Optimal Treatment Modality for Patients With Advanced Cervical Cancer
02/23/2023
Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.
Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.
Data presented at the 2023 ESMO...
02/23/2023
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use